Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 27;8(4):1032-1036.
doi: 10.1182/bloodadvances.2023011184.

Estimation of eligibility for and response to CAR-T therapy in the United States

Alyson Haslam  1 , Tracy Beth Hoeg  1 , Vinay Prasad  1
Affiliations

Estimation of eligibility for and response to CAR-T therapy in the United States

Alyson Haslam et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: V.P. acquired research funding from Arnold Ventures; reports royalties from Johns Hopkins Press, Medscape, and MedPage; honoraria from Grand Rounds/lectures from universities, medical centers, nonprofits, and professional societies; provided consultancy for UnitedHealthcare and OptumRX; and has other participation in Plenary Session podcast, which has backing via Patreon, YouTube, and Substack. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Percentage estimates of patient eligibility for CAR-T therapies that have received US FDA approval.
See this image and copyright information in PMC

Comment in

  • Maybe you can't drive this CAR?
    Derman BA. Derman BA. Blood Adv. 2024 Feb 27;8(4):1030-1031. doi: 10.1182/bloodadvances.2023012244. Blood Adv. 2024. PMID: 38411994 Free PMC article. No abstract available.

References

    1. National Cancer Institute CAR T cells: engineering patients’ immune cells to treat their cancers. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells Updated March 2022.
    1. Prasad V. Immunotherapy: tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. Nat Rev Clin Oncol. 2018;15(1):11–12. - PubMed
    1. Rosenbaum L. Tragedy, perseverance, and chance - the story of car-t therapy. N Engl J Med. 2017;377(14):1313–1315. - PubMed
    1. Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284–1295. - PubMed
    1. Liu Z, Zhou J, Yang X, et al. Safety and antitumor activity of GD2-specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023;22(1):3. - PMC - PubMed

Publication types

MeSH terms

Substances